Impact of genetic targets on prostate cancer therapy

Hassan Sheikh, Junaid Abdulghani, Suhail Ali, Raghu Sinha, Alan Lipton

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Scopus citations

Abstract

Given the global incidence of prostate cancer and its sociological impact, it remains a challenging disease to clinicians and researchers alike. In the last few years several new drugs have been added to the armamentarium of prostate cancer therapy and offers survival benefit to patients with prostate cancer. However, effective drugs are still needed that offer extended survival benefit and alter the natural history of the disease. Recent efforts have focused on better understanding the underlying biology and genetic heterogeneity of the disease and identified novel targets that can be utilized for drug development and therapeutics in the future. In this review we present an overview of the genetic landscape of prostate cancer, novel targets in the prostate cancer therapy and the results of key clinical trials of these novel drugs.

Original languageEnglish (US)
Title of host publicationImpact of Genetic Targets on Cancer Therapy
EditorsWafik El-Deiry
Pages359-383
Number of pages25
DOIs
StatePublished - Feb 15 2013

Publication series

NameAdvances in Experimental Medicine and Biology
Volume779
ISSN (Print)0065-2598

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Sheikh, H., Abdulghani, J., Ali, S., Sinha, R., & Lipton, A. (2013). Impact of genetic targets on prostate cancer therapy. In W. El-Deiry (Ed.), Impact of Genetic Targets on Cancer Therapy (pp. 359-383). (Advances in Experimental Medicine and Biology; Vol. 779). https://doi.org/10.1007/978-1-4614-6176-0-17